Botox Stats
Some intersting info on Botox provided by the
Manufacturer of Botox
BOTOX® Cosmetic and BOTOX® (Botulinum Toxin Type
A) By the Numbers
· 3,181,592:
Number of BOTOX® Cosmetic treatments administered in the United States in 2006 alone[i]
· 1,000,000s:
People who received treatment with BOTOX® for medical and aesthetic purposes around the world[ii]
· 300,000:
Number of men who received treatment with BOTOX® Cosmetic in 2006[iii]
· 10,000:
People in clinical trials[iv]
· 3,000:
Publications on Botulinum Toxin Type A in scientific and medical journals[v]
· 100:
Years of study into botulinum neurotoxins[vi]
· 97:
Percentage of people satisfied with their BOTOX® Cosmetic treatment based on a survey of approximately 1,000 patients[vii]
· 75: Countries around the world who have approved use of BOTOX®
· 20: BOTOX® indications approved by regulatory authorities around the world, including the aesthetic indication
· 18: Years since U.S. Food and Drug Administration (FDA) approved BOTOX® to treat excessive eye blinking and crossed eyes
· 11: Descriptor for the glabellar (vertical) lines between the brows which can be treated with BOTOX® Cosmetic, that can help improve one’s overall facial appearance
· 8: Years since FDA approval of BOTOX® for the treatment of cervical dystonia (painful neck twisting condition) in adults
· 6: Years since FDA approval of BOTOX® Cosmetic for the treatment of the moderate to severe glabellar (vertical) lines between the brows in adults 18 to 65
· 4: Years since FDA approval of BOTOX® for the treatment of severe primary hyperhidrosis (excessive underarm sweating) inadequately managed with topical agents
· 1: Rank of BOTOX® Cosmetic on list of “Top 5 Surgical & Nonsurgical Physician Administered Cosmetic Procedures,”[vii according to American Society for Aesthetic Plastic Surgeryi]
About BOTOX® (Botulinum Toxin Type A)
BOTOX® is a medical product that contains tiny amounts of highly purified botulinum toxin protein refined from a bacterium. The product is administered in small therapeutic doses by injection directly into the affected area, and works by blocking the release of acetylcholine (a neurotransmitter that signals the muscles to contract) at the neuromuscular junction.
BOTOX® neurotoxin has since received approval in December 2000 for the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. In 2002, with dosing specific to treat frown lines between the eyebrows, the product was approved by the FDA for the temporary improvement in the appearance of moderate to severe glabellar lines (the vertical “frown lines” between the eyebrows) in adult men and women aged 65 and younger, under the name BOTOX® Cosmetic. More recently, in July 2004, BOTOX® was granted FDA approval for the treatment of severe primary axillary hyperhidrosis (excessive underarm sweating) that is inadequately managed with topical agents.
